| abstract |
Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer. The second active agent of the therapeutic method disclosed is a histone deacetylase inhibitor, selected from Belinostat, MS-275 and Romidepsin, which is administered in combination with the TOR kinase inhibitor. |